Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in Underserved Populations

The treatment of vulnerable populations must be prioritized in order to accomplish the WHO HCV elimination goals by 2030, including patients with mental health disorders, incarcerated patients, and homeless patients. Simplification of the treatment cascade and rapid treatment start is key to achieve this goal, even more so in the COVID-19 era.